Ampio Announces Delay in Ampion Results Due to Flaw in Phase III Testing

On August 21, 2014, the share price of Ampio's stock dropped 24% after the company announced that the recent phase III study of the drug Ampion may have been flawed and final results would be delayed. In a letter to shareholders on August 25, 2014, the company explained that during the study there was a point where the chemical being tested allegedly froze, which is believed to have affected the level of active ingredients in the dosage of Ampion.

Robbins Arroyo LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested.

Attorney Advertising. Past results do not guarantee a similar outcome.

Easily Send & Share Press Releases

GlobeNewswire, a NASDAQ OMX company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.